Business
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal
About this update from Agenus Inc.
[{"type":"text","content":"\n\nAt a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median of four prior treatments, more than double the survival rate reported for available treatments\n\n\n\nBotensilimab/balstilimab combination data update selected for late-breaking oral session at the ESMO-GI conference in June 2023\n\n\n\nFDA granted Fast Track Designation to the botensilimab/balstilimab combination in colorectal cancer in April 2023\n\n\n\nAt a plenary session at SGO, botensilimab/balstilimab combination showed 33% overall response rate in platinum-resistant ovarian cancer patients\n\n\n\nPhase II ACTIVATE trials expected to fully enroll in second half of 2023\n\n\n\nAGEN2373 monotherapy data to be presented at ASCO in June 2023\n\n\n\nBalstilimab/zalifrelimab data in the treatment of sarcoma to be presented at ASCO oral session in June 2023\n\n\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nAgenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today provided a corporate update and reported financial results for the first quarter 2023.\n\n\n\"With over 350 patients dosed with botensilimab in our Phase 1 study, we have demonstrated 20-50% response rates in 9 solid tumor cancers. These results suggest that botensilimab could provide significant benefit to patients who have not responded to or failed other available treatments,” said Dr. Garo Armen, Chief Executive Officer of Agenus. “Agenus is committed to advancing our development programs to make botensilimab available to patients ASAP.\"\n\n\n\n\nBotensilimab Combination\n\n\nUnprecedented activity in 70 patients with non-MSI-H colorectal cancer and 24 patients with recurrent platinum resistant/refractory ovarian cancer:\n\n\n\nAgenus presented botensilimab/balstilimab combination data at a late-breaking oral session at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI) in January 2023 and at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer in March 2023\n\n\n\nThe combination showed unprecedented responses and survival benefit in 70 patients with non-microsatellite instability-high (non-MSI-H) colorectal cancer, including:...